Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates.

MLA

Milani, Michela, et al. “Liver-Directed Lentiviral Gene Therapy Corrects Hemophilia A Mice and Achieves Normal-Range Factor VIII Activity in Non-Human Primates.” Nature Communications, vol. 13, no. 1, May 2022, p. 2454. EBSCOhost, https://doi.org/10.1038/s41467-022-30102-3.

APA

Milani, M., Canepari, C., Liu, T., Biffi, M., Russo, F., Plati, T., Curto, R., Patarroyo-White, S., Drager, D., Visigalli, I., Brombin, C., Albertini, P., Follenzi, A., Ayuso, E., Mueller, C., Annoni, A., Naldini, L., & Cantore, A. (2022). Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates. Nature Communications, 13(1), 2454. https://doi.org/10.1038/s41467-022-30102-3

Chicago

Milani, Michela, Cesare Canepari, Tongyao Liu, Mauro Biffi, Fabio Russo, Tiziana Plati, Rosalia Curto, et al. 2022. “Liver-Directed Lentiviral Gene Therapy Corrects Hemophilia A Mice and Achieves Normal-Range Factor VIII Activity in Non-Human Primates.” Nature Communications 13 (1): 2454. doi:10.1038/s41467-022-30102-3.